November 20, 2015 / 3:26 PM / 3 years ago

BUZZ-U.S. STOCKS ON THE MOVE-Sarepta, Sprint, KaloBios, Mentor Graphics

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter,; for the Morning News Call newsletter, U.S. stock indexes rose on Friday and were on track for their best weekly performance since October. The Dow Jones industrial average was up 0.96 percent at 17,903.55, the S&P 500 was up 0.69 percent at 2,095.66 and the Nasdaq Composite was up 0.64 percent at 5,106.267.

** BIOMARIN PHARMACEUTICAL INC, $98.595, -4.38 pct

** SAREPTA THERAPEUTICS INC, $32.9017, +26.21 pct

** PTC THERAPEUTICS INC, $28.5, -5.38 pct

U.S. Food and Drug Administration staff reviewers said clinical data to date did not merit approving the drug developer’s muscle-wasting disorder drug.

Shares of Sarepta, which is developing rival product for DMD, rose. Shares of PTC, whose experimental DMD drug has also failed a late-stage study, fell.

** SPRINT CORP, $3.81, -5.93 pct

The company said it would raise about $1.1 billion in cash by selling and then leasing back some leased-out mobile devices to a company whose backers include SoftBank Group Corp. Sprint also cut its full-year adjusted EBITDA forecast to $6.8 billion-$7.1 billion from $7.2 billion-$7.6 billion, based on the deal and the inclusion of “transformation program costs.”

** ABERCROMBIE & FITCH, $23.29, +19.50 pct

The teen apparel retailer said its quarterly profit more than doubled and same-store sales fell less than expected as company boosted gross margin by offering fewer promotions and controlling costs.

** NIKE INC, $132.46, +5.31 pct

The world’s No. 1 sportswear maker said its board approved a new $12 billion share buyback program and a two-for-one split of its class A and class B shares.

** FOOT LOCKER INC, $64.51, +4.84 pct

The footwear retailer reported better-than-expected quarterly profit and sales, helped by strong demand for basketball and running shoes.

** HORIZON PHARMA PLC, $20.26, +7.65 pct

** DEPOMED INC, $18.99, -2.06 pct

The Ireland-based drugmaker said it had withdrawn its offer to acquire Depomed following a court ruling that granted Depomed’s motion for preliminary injunctive relief on Horizon’s alleged used of confidential information.

** PEABODY ENERGY CORP, $11.73, -0.93 pct

** CLOUD PEAK ENERGY INC, $2.91, -3.96 pct

** CONSOL ENERGY INC, $7.74, -1.15 pct

UBS cut its long-term sea-borne thermal coal price forecast by 33 percent and hard coking coal price forecast by 20 percent due to lack of growth in sea-borne demand and expectations of deflated capital and operating expenses.

** APTOSE BIOSCIENCES INC, $3.71, -30.13 pct

The drug developer said the U.S. Food and Drug Administration put its early-stage trial on a cancer drug on hold after a review found a malfunctioning infusion pump at a clinical site where the tests were being held.

** KALOBIOS PHARMACEUTICALS INC, $20.95, +101.44 pct

The drug developer said it appointed Martin Shkreli CEO after the controversial head of Turing Pharmaceuticals led a group of investors to buy 70 percent of its outstanding shares.

** MENTOR GRAPHICS CORP, $19.16, -31.03 pct

JP Morgan rated Mentor’s stock “sell” after the electronic hardware and software design provider set its fourth-quarter and full-year revenue forecasts below Wall Street estimates.

** NIMBLE STORAGE INC, $10.88, -46.64 pct

The data storage maker reported bigger-than-expected quarterly loss as it shifts to flash-centric architectures from disk-centric architectures.

** HABIT RESTAURANTS INC, $23.095, +6.14 pct

The fast-casual burger chain operator postponed its previously announced secondary offering “in light of current capital market conditions”.

** BUILDERS FIRSTSOURCE INC, $13.3, -1.92 pct

The building products supplier said shareholder Warburg Pincus would offer 7 million shares. Builders FirstSource had 109.3 million shares outstanding as of Tuesday, according to Thomson Reuters data.

** PFIZER INC, $32.405, +0.36 pct

** ALLERGAN PLC, $311.28, +3.06 pct

Pfizer is negotiating a 2-3 percent break-up fee with Allergan, people familiar with the matter said. If Pfizer were to walk away from Allergan, it would have to pay $3 billion to $4.5 billion based on a $150 billion deal value, making it one of the highest ever break-up fees in dollar terms.

** INTUIT INC, $102.74, +5.46 pct

The tax-preparation software maker estimated full-year adjusted profit of $3.45-$3.50 per share, above the average analyst estimate of $3.43.

** ROSS STORES INC, $50.1, +8.44 pct

At least 3 brokerages raised their price targets by as much as $2 to as high as $61 after the off-price retailer increased its full-year 2015 profit forecast to $2.45-$2.48 per share from $2.40-$2.45

** WORKDAY INC, $81.59, -3.21 pct

The human resources software maker forecast current-quarter revenue below analysts’ estimates and reported a bigger net loss for the third quarter.

** NATIONAL BANK OF GREECE, $0.2666, -28.14 pct

The troubled Greek lender priced its share offering at 0.02 euros per share, or at 0.30 euros per share reflecting 1-for-15 reverse share split.

Reporting by Nikhil Subba in Bengaluru; Editing by Kirti Pandey

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below